A drug to treat early-stage Alzheimer's, donanemab, has received a positive opinion from the EMA and is close to authorization in the European Union.
Cristina Petrache
Health
Foto unsplash.com
Always see our news on Google
Donanemab, a new drug developed by Eli Lilly for the treatment of early forms of Alzheimer's disease, has received a favorable opinion from the EMA committee, recommending its authorization. The drug, which is intended for patients who are non-carriers or heterozygous for apolipoprotein E ε4, has been shown in clinical trials to slow the progression of cognitive impairment. The drug will be available as an infusible solution, and common side effects include amyloid-associated imaging abnormalities and headache. The final authorization decision rests with the European Commission.
Sources
Un nou tratament pentru boala Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Latest News
08:48
EU member states are calling for the introduction of a tax on oil companies, as a result of their increased profits due to the war in the Middle East.
08:29
The former Minister of Defense denounces corruption in Ukraine and says that it hinders the achievement of victory in the war with Russia.
08:09
Vladimir Putin declared that Ukraine has opened the "Pandora's Box" through attacks on Russian economic infrastructure: "They should expect a response"
07:57
A fire broke out at a medical center in Arad. Three hospitalized patients in the respective unit were transported to the hospital, complaining of mild smoke inhalation and panic attacks.
07:36
Canada will impose tariffs on products imported from the USA in response to the new 50% taxes imposed by Donald Trump.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
